Science Applications International Corporation
(SAIC) (NYSE: SAI) announced today the appointment of Dr. David Heimbrook
as chief executive officer of SAIC-Frederick, Inc.
, a wholly owned subsidiary of SAIC, effective May 31.
Heimbrook will succeed Dr. Larry Arthur, who has served as CEO since 2000 and will remain with SAIC-Frederick as chief scientist.
will be responsible for the comprehensive management and oversight of all scientific and business activities conducted on the contract.
He will lead SAIC-Frederick's staff of approximately 2,000 scientific, technical, and support professionals who perform basic and applied research in cancer and AIDS, and maintain a full suite of advanced technologies in areas such as nanotechnology, genomics and biomedical imaging.
Heimbrook brings more than 20 years of experience and progressive responsibility in cancer research, translational research and organizational management.
Prior to joining SAIC-Frederick, he was the global head of discovery for the Oncology Discovery and Translation Area of Hoffman-LaRoche, Inc.
Leading three cancer research sites, Heimbrook
was responsible for developing and implementing Roche's oncology research strategy, including personalized healthcare and partnering relationships, and transitioning compounds through clinical proof-of-concept to pivotal registration studies.
Heimbrook previously held positions with Merck Research Laboratories and Smith Kline & French Laboratories.
Heimbrook earned his Ph.D. in molecular biophysics and biochemistry from Yale University, a master's degree in molecular biophysics and biochemistry from Yale University, and a bachelor's degree in chemistry from Duke University.